InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,722.26
(
-0.19%
)
US TECH 100
19,432.80
(
0.00%
)
Dow Jones
41,914.75
(
-0.70%
)
Brent Oil
71.22
(
-2.70%
)
Bitcoin
63,823.68
(
1.09%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 201

Sunday, 06/17/2018 12:04:49 PM

Sunday, June 17, 2018 12:04:49 PM

Post# of 438
MGTA is a biotech ipo with Ph2 data due in H2/18 and a substantial cash runway.

Technology involves bone marrow transplant using gene modified stem cells.

MGTA intends to use this technology to target the following conditions:

* Blood cancers
* Myelodisplastic syndromes
* Sickle Cell Disease
* beta-Thalessemia
* M.S.
* Scleraderma

The Ph2 data will be a clinical POC study for blood disorders.

After the IPO, MGTA will have a cash runway of greater than 5 years at the present burn rate.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up